List of publications on aHUS published by aHUS Alliance:
December 8, 2013: New Data Presented at ASH Annual Meeting Enhance Understanding of aHUS to Provide Optimal Care for Patients Press release here.
November 9, 2013: Soliris® (eculizumab) Inhibits TMA and Improves Renal Function in Pediatric and Adult Patients with atypical Hemolytic Uremic Syndrome (aHUS) Press release here.
Feb. 19, 2015: Omeros Corporation’s Phase 2 OMS721 Trial Resulting in Extended Access for Compassionate Use - The Company Agrees to Physician Request to Continue Treatment of Patients with aHUS - Press release here.
July 23, 2015: FDA Grants “Fast Track” to Omeros’ Complement Inhibitor OMS721 for aHUS Press release here.
August 18, 2015: Omeros Announces Additional Positive Data in OMS721 Phase 2 Clinical Trial – Company Plans for Phase 3 Program Based on Consistent Response in TMA Patients – Press release here.
December 2, 2015 Ra Pharmaceuticals Announces Initiation of First-in-Human Clinical Trial of Novel Complement C5 Inhibitor Press release here